IONS - Ionis Pharmaceuticals, Inc.
| Previous Close | 43.83 |
| Open | 43.76 |
| Bid | 43.15 x 900 |
| Ask | 44.75 x 3200 |
| Day's Range | 43.51 - 44.71 |
| 52 Week Range | 39.07 - 65.51 |
| Volume | 990,361 |
| Avg. Volume | 1,324,766 |
| Market Cap | 5.603B |
| Beta | 3.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.05 |
| Earnings Date | Aug 6, 2018 - Aug 10, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 61.91 |
- CNBC Videos•20 days ago
Cramer's lightning round: Corning's stock is an unnecessa...
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including an industrial play.
- Motley Fool•yesterday
3 Top Biotech Stocks to Buy Right Now
Want to invest in this promising industry but don't know where to start? Here are three stocks that can get the ball rolling.
- Motley Fool•9 days ago
Why Akcea Therapeutics Rocketed Higher Today
An FDA advisory committee endorsed the biotech's lead drug, but an approval is far from a slam dunk.
- Market Exclusive•9 days ago
Akcea and Ionis Just Got A Major Boost
We are closing in on the end of another week in the biotechnology space just as was the case last week, we’ve seen plenty of movement in the sector on the back of a number of fresh releases. Here is a look at the most pertinent and a description of what it means for the […] The post Akcea and Ionis Just Got A Major Boost appeared first on Market Exclusive.
- GlobeNewswire•10 days ago
FDA Advisory Committee Votes in Favor of WAYLIVRA for Treatment of Familial Chylomicronemia Syndrome
Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS) today announced that the U.S. Food and Drug Administration’s (FDA) Division of Metabolism and Endocrinology Products Advisory Committee voted 12-8 to support approval of WAYLIVRATM (volanesorsen) for the treatment of people with familial chylomicronemia syndrome (FCS). The committee’s non-binding recommendation will be considered by the FDA in its review of Akcea’s New Drug Application for WAYLIVRA. The PDUFA date for completion of the review of WAYLIVRA is August 30, 2018. “We look forward to working with the FDA to complete the final stages of regulatory review for WAYLIVRA.
- Motley Fool•11 days ago
Ionis Pharmaceuticals Prepares for Launch
The biotech has the potential for two FDA approvals this year.
Markit•11 days agoSee what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Thomson Reuters StreetEvents•11 days ago
Edited Transcript of IONS earnings conference call or presentation 4-May-18 3:30pm GMT
Q1 2018 Ionis Pharmaceuticals Inc Earnings Call
Motley Fool•13 days agoIonis Pharmaceuticals (IONS) Q1 2018 Earnings Conference Call Transcript
IONS earnings call for the period ending March 31, 2018.
- InvestorPlace•16 days ago
10 Ionis Pharmaceuticals Inc Earnings Highlights
The following are a few things for investors to know about Ionis Pharmaceuticals Inc’s most recent earnings report. This is down from its earnings per share of 7 cents reported in the same period of the year prior. Ionis Pharmaceuticals Inc also reported a net loss of $10.81 million for the first quarter of 2018.
- Zacks•16 days ago
Ionis (IONS) Beats Earnings & Misses Revenues in Q1
Ionis Pharmaceutical (IONS) reported positive quarter with earnings beating estimates while revenues missing the same.
- MarketWatch•16 days ago
Ionis Pharma shares lift 4% after Q1 profit, revenue beats
Ionis Pharmaceuticals Inc. shares rose 3.9% in premarket trade Friday after the company reported first-quarter profit and revenue beats. The company reported a loss of $1.42 million, or a loss of 1 cent per share, after earnings of $8.96 million, or 7 cents per share, in the year-earlier period. Ionis said it and Biogen expect their recent deal to close in the second quarter.
- Associated Press•16 days ago
Ionis Pharmaceuticals: 1Q Earnings Snapshot
On a per-share basis, the Carlsbad, California-based company said it had a loss of 1 cent. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
- PR Newswire•16 days ago
Ionis Reports First Quarter 2018 Financial Results
Total revenues increased by 25%, driven by SPINRAZA royalties More than $2 billion of cash expected upon closing of Biogen transaction Expanded strategic neurology research collaboration with Biogen and ...
- Zacks•19 days ago
What's in the Cards for Ionis (IONS) This Earnings Season?
Ionis Pharmaceuticals (IONS) earns $30 million in license payments from AstraZeneca. Spinraza witnesses strong first quarter as announced by Biogen in its earnings release.
- Motley Fool•20 days ago
Biogen's $1 Billion Bet on Ionis
Biogen announced it would pay nearly $1 billion for expanded access to Ionis’ pipeline. Was it worth it?
- Motley Fool•22 days ago
Is Biogen Inc. a Buy?
Biogen's stock has had an awful 2018 so far. Is this top biotech now an incredible bargain?
- Motley Fool•24 days ago
A Promising Step for Medical Marijuana
Medical marijuana enthusiasts, get hyped -- GW Pharma’s advisory committee meeting results could mean huge things for the industry.
- GlobeNewswire•24 days ago
Akcea Therapeutics Announces Presentations on Volanesorsen and FCS at the National Lipid Association Scientific Sessions
CAMBRIDGE, Mass. and LAS VEGAS, April 26, 2018-- Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat people with serious and ...
- GlobeNewswire•24 days ago
Akcea Therapeutics to Hold First Quarter 2018 Financial Results Webcast
CAMBRIDGE, Mass., April 26, 2018-- Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Thursday, May 3 rd at 4:30 p.m. Eastern Time ...
- Zacks•25 days ago
Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales
The biotech sector grabbed headlines last week as a couple of biotechs reported results while few others came out with pipeline updates.
Market Realist•25 days agoBiogen-Ionis Expansion Builds on Spinraza Success
On April 20, Biogen (BIIB) and Ionis Pharmaceuticals (IONS) announced the expansion of their strategic collaboration to develop drug candidates targeted at a range of neurological diseases. This key move builds on the productive collaboration between the two companies that led to the development of Spinraza, the first and only approved treatment for patients with spinal muscular atrophy, along with two antisense drug candidates that are currently under development.
Market Realist•25 days agoHow Did Biogen’s Spinraza Perform in 1Q18?
In 1Q18, Biogen’s (BIIB) Spinraza generated revenues of $364 million compared to $47 million in 1Q17 and $363 million in 4Q17. In 1Q18 in the US and international markets, Spinraza generated revenues of $188 million and $176 million, respectively, compared to $46 million and $1 million, respectively, in 1Q17. Spinraza is used in the treatment of individuals with spinal muscular atrophy.
Motley Fool•26 days agoWhy Ionis Pharmaceuticals Crashed Today
Two news events in one day have the biotech seeing red.
- PR Newswire•26 days ago
New Data from IONIS-HTT Rx Phase 1/2 Study Demonstrates Correlation Between Reduction of Disease-causing Protein and Improvement in Clinical Measures of Huntington's Disease
Results from exploratory analyses of data from the study demonstrated correlations between reductions in mutant huntingtin (mHTT), the disease-causing protein, and improvements in clinical measures of Huntington's disease.
